UNSPSC 51203303: Pomalidomide

This classification denotes an immunosuppressant, a biological preparation with the molecular formula C13H11N3O4 and that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D2UX06XLB5, chemically known as 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione or 4-Aminothalidomide but more commonly known as pomalidomide, which bears US NIH Compound Identifier 134780. The term POMALIDOMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 1, 2008, List 59).

European Medicines Agency schedules pomalidomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33379. SMILES: C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N.

UNSPSC 51203303 Pomalidomide is a Commodity code that captures specialty pharmaceutical products procured by state and local health agencies. Recent state and local opportunities tagged under this code show actual purchases of naloxone, drug deactivation systems, and antibiotic pharmaceuticals through cooperative purchasing vehicles and direct competitive bidding. State and local issuing bodies soliciting under the code include county health departments and state health agencies. The scope reflects procurement of finished pharmaceutical products for public health purposes, including emergency response supplies and community health initiatives, with vendors responsible for meeting regulatory compliance, insurance, and delivery requirements.

Geographic activity appears concentrated in Florida and Illinois based on recent opportunities. Seminole County, Florida solicited naloxone and safe drug deactivation systems via IFB 60459723LAS with a July 26, 2023 response deadline, seeking 1,900 units of naloxone and 800 deactivation systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 (Bid 26-482DPH-PREPD-B-53392) for antibiotic products under a 12-month initial term with two renewal options, totaling $2,999,999.11 over the contract life. The Illinois award used an Invitation for Bid process and identified no set-aside or preference requirements.